Company Summary - Hendi Pharmaceutical (SZ 301211) announced that as of the date of the announcement, Liu Yanchao has pledged approximately 18.79 million shares, accounting for 7.06% of his total holdings. Liu Wenchao has also pledged approximately 18.79 million shares, representing 7.06% of his holdings. Liu Sichao has pledged approximately 18.79 million shares, which is 7.06% of his holdings. Liu Tianchao has pledged approximately 16.12 million shares, making up 6.06% of his holdings [1][1][1] - For the fiscal year 2024, Hendi Pharmaceutical's revenue composition is as follows: raw materials account for 79.88%, formulations account for 19.11%, and others account for 1.01% [1][1][1] - As of the announcement, Hendi Pharmaceutical has a market capitalization of 6.6 billion yuan [1][1][1]
亨迪药业：刘妍超累计质押股数约为1879万股，刘雯超累计质押股数约为1879万股